[Prevention of CVD in patients with CKD]

Area of Science:

• Nephrology
• Cardiology
• Endocrinology

Background:

• Chronic kidney disease (CKD) involves proteinuria and kidney dysfunction, often linked to metabolic disorders like diabetes, dyslipidemia, and hypertension.
• Cardiovascular disease (CVD) is a primary cause of morbidity and mortality in CKD patients.
• Metabolic disorders are implicated in the shared pathological mechanisms of CKD and CVD.

Purpose of the Study:

• To explore the potential of early intervention in metabolic disorders to prevent CKD.
• To investigate the role of angiotensin II and aldosterone blockers in mitigating CKD and associated CVD.
• To highlight the link between metabolic health and kidney and cardiovascular outcomes.

Main Methods:

• Review of recent clinical studies on angiotensin II blockade (ARB and ACEI) efficacy in CKD and CVD.
• Analysis of pathological mechanisms connecting metabolic disorders, CKD, and CVD.
• Exploration of therapeutic strategies involving blockers for angiotensin II and aldosterone.

Main Results:

• Angiotensin II blockade (ARB and ACEI) has demonstrated effectiveness in reducing both CKD progression and CVD.
• Metabolic disorders significantly contribute to the pathogenesis of CKD and CVD.
• Early intervention targeting metabolic pathways is crucial for managing kidney and cardiovascular health.

Conclusions:

• Earlier intervention in metabolic disorders, using blockers for angiotensin II and aldosterone, shows promise in preventing CKD.
• This therapeutic strategy may also prevent cardiovascular disease associated with chronic kidney disease.
• Managing metabolic disorders is key to preserving kidney function and reducing cardiovascular risk in affected individuals.